Novel, oral anti-inflammatory compounds for the treatment of rheumatoid arthritis

Rheumatoid arthritis patients who don’t respond to current treatments could soon have an oral pill as an alternative to injectable drugs. Rheumatoid arthritis affects 1% of the global population, but up to 40% of patients get no benefit from existing therapies. Modern Biosciences has developed a new class of anti-inflammatory compounds that work differently from current drugs: they reduce inflammation while also protecting bone integrity, which existing treatments often fail to do. The compounds are taken orally, offering a simpler alternative to injectable ‘biologics’—the fastest-growing class of RA drugs. They also work well alongside existing treatments, potentially extending how long those drugs remain effective. If this project succeeds in identifying a lead compound and completing preclinical development, it could lead to clinical trials for a new RA therapy. Beyond RA, the same compounds may prove effective in other autoimmune disorders. For the roughly 40% of patients who currently cycle through ineffective treatments, an oral drug that preserves bone health would represent a practical improvement in daily disease management—no injections, fewer failed therapies, and less long-term joint damage.